Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.07 EPS

Vericel (NASDAQ:VCEL - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.31 by $0.07, Zacks reports. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $75.38 million during the quarter, compared to analysts' expectations of $76.47 million.

Vericel Stock Performance

Shares of VCEL traded down $2.21 during trading hours on Monday, hitting $49.08. 441,822 shares of the company were exchanged, compared to its average volume of 406,553. The firm's 50 day moving average is $57.20 and its 200-day moving average is $51.87. Vericel has a 52 week low of $39.12 and a 52 week high of $63.00. The company has a market cap of $2.42 billion, a PE ratio of 822.00 and a beta of 1.72.

Analyst Ratings Changes

A number of equities analysts recently commented on VCEL shares. Stephens reaffirmed an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. Truist Financial reaffirmed a "buy" rating and issued a $61.00 target price (down previously from $67.00) on shares of Vericel in a research report on Monday. StockNews.com lowered Vericel from a "hold" rating to a "sell" rating in a research report on Friday. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vericel in a research report on Friday. Finally, BTIG Research lifted their target price on Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat, Vericel currently has a consensus rating of "Moderate Buy" and an average target price of $62.29.

Remove Ads

Insider Buying and Selling

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now directly owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jonathan Siegal sold 1,092 shares of Vericel stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total value of $67,693.08. Following the sale, the insider now directly owns 1,206 shares in the company, valued at approximately $74,759.94. This trade represents a 47.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,100 shares of company stock worth $618,872. 5.20% of the stock is currently owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.